Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.5.0.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Operating costs and expenses:        
Research and development $ 891,828 $ 816,318 $ 3,526,322 $ 2,407,141
IPR&D expense 0 0 39,500,000 0
General and administrative 1,359,801 2,984,484 4,339,844 4,723,109
Loss from operations (2,251,629) (3,800,802) (47,366,166) (7,130,250)
Other income (expense):        
Change in fair value of derviative liability 241,298 (1,344,542) 2,146,587 (1,344,542)
Loss on issuance of hybrid debt instrument (106,566) 0 (1,690,787) (59,612)
Loss on conversion of debt 0 0 (6,187,337) 0
Other income (expense) (13,440) (50,526) (26,991) (216,429)
Interest income 4 67 31 1,155
Interest expense (341,648) (127,896) (690,118) (130,408)
Total non-operating expense, net (220,352) (1,522,897) (6,448,612) (1,749,836)
Net loss (2,471,981) (5,323,699) (53,814,778) (8,880,086)
Other comprehensive loss from foreign currency translation adjustment 0 5,112 0 (321,942)
Total comprehensive loss $ (2,471,981) $ (5,318,587) $ (53,814,778) $ (9,202,028)
Net loss per share of common stock, basic and diluted $ (.28) $ (1.26) $ (7.54) $ (2.10)
Weighted-average shares of common stock outstanding, basic and diluted 8,987,145 4,228,974 7,134,352 4,223,905